FDA issues warning letter over Cymbalta physician promo

Share this article:

The FDA has issued Eli Lilly a warning letter over effectiveness claims the company made in a 2005 promotional mailer to physicians for its blockbuster antidepressant/nerve pain treatment Cymbalta.
 
In a letter posted to the FDA's Web site on Tuesday, the agency said Lilly's promotion intended to promote its indication as a treatment for diabetic nerve pain was “false and misleading” and omitted some of the most serious and important risk information associated with its use.

The agency asked that Lilly stop using the material or similar promotions.

A Lilly spokesman told The Indianapolis Star that the company is working with the FDA "to gain a greater understanding of their concerns."

The spokesman said Lilly will take action once it has "more clarity" on the agency's comments.

Launched in 2004, Cymbalta has become Lilly's fastest-growing drug, with global sales $1.3 billion in 2006.

Share this article:

Email Newsletters

More in News

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.

Shire, AbbVie join forces for $55B

Shire, AbbVie join forces for $55B

The deal includes a $1.6-billion fee if AbbVie tries to walk away.

Next target for hep. C drugmakers: co-infections

Next target for hep. C drugmakers: co-infections

An international AIDS conference this weekend kicked off a new battle in the war against hepatitis C: demonstrating high cure rates in those who are co-infected.